Overview

An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis

Status:
NOT_YET_RECRUITING

Trial end date:
2027-09-10

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.

Phase:

PHASE1

Details

Lead Sponsor:

Chongbo Zhao

Collaborator:

Gracell Biotechnologies (Shanghai) Co., Ltd.